Gaby Danan, MD, PhD, was the EU QPPV for Sanofi until his retirement in 2010. He has served on the Council for International Organizations of Medical Sciences and International Conference on Harmonisation Expert Working Groups, as the European Federation of Pharmaceutical Industries and Associations Clinical Safety E2B topic leader and co-chaired the EudraVigilance Expert Working Group from its inception until 2009. Dr. Danan co-published the Roussel Uclaf Causality Assessment Method for drug-induced liver injury, has authored papers on pharmacovigilance definitions and methodologies, chaired the DIA 2010 Annual Meeting, serves on the DIA Safety Training Committee, and instructs several DIA training courses.

Philippe Nuss, MD, PhD is psychiatrist in charge of the first episode and dual diagnosis unit of the Department of adult psychiatry at the Saint-Antoine University Hospital in Paris. His clinical work is mainly dedicated to the treatment of at-risk mental states and first psychiatric episodes. He is also strongly involved in initial and post graduate teaching in particular clinical pharmacology at the ECNP Summer School, Oxford, UK and various Universities all-over the world. He is also strongly involved in patient and family psycho education. Dr Nuss is an expert at the French Agency for Drug Market Authorization and at the National Institute for Health Education (INPES).

Dr. L. Valeyrie–Allanore is a dermatological expert specialised in severe cutaneous adverse drug reactions. She is a member of the RegiSCAR network and has authored numerous papers and book chapters on severe cutaneous adverse reactions.